Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH – Get Free Report) has earned a consensus rating of “Buy” from the seven brokerages that are presently covering the firm, Marketbeat Ratings reports.

On November 14 th, 2024, Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) reported third quarter 2024 financial and operational results and filed its Form 10-Q with the SEC. Reviva provided ...

Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) had its price objective lowered by HC Wainwright from $14.00 to $11.00 ...

Oppenheimer 35th Annual Healthcare Life Sciences Conference Format: Corporate update Date: Wednesday, February 12, 2025 Time: 2:40 p.m. ET Location: Virtual Webcast Link: Click Here ...

Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) reported preliminary results from its open label extension (OLE) portion of the Phase III RECOVER trial. Brilaroxazine showed a favorable long ...

Vandana Singh Analyst Assessment On Reviva Pharmaceuticals' Positive Schizophrenia Trial Data - Sees More Than 200% Upside In Stock Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) shares are ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

1 Day RVPH 1.06% DJIA -0.32% Russell 2K -0.30% Health Care/Life Sciences -0.52% ...